Product Detail
基本信息
| Size | 10ug |
|---|---|
| Expression Host | Human Cells |
| Tag | C-6His |
物理性质
| Molecular Weight | 16.2 KDa |
|---|---|
| Apparent Molecular Weight | 17-26 KDa, reducing conditions |
| Form | Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
| Purity | Greater than 95% as determined by reducing SDS-PAGE. |
活性与内毒素
| Endotoxin Level | Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test. |
|---|---|
| Activity | Loaded Biotinylated Human IL-17RA -His-Avi(Cat#CY78) on SA Biosensor, can bind Mouse IL-17A-His(Cat#CX14) with an affinity constant of 12.6 nM as determined in BLI assay. |
储存与运输
| Reconstitution | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
|---|---|
| Storage | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| Shipping Condition | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. |
详细说明
| Background | Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. Mature mouse IL-17A shares 61% and 89% amino acid sequence identity with human and rat IL-17A, respectively. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation. |
|---|
